ClinicalTrials.gg
TerminatedNCT00846781DEFYUpdated Nov 6, 2015

Study 08-114 Open-label Extension of Study 08-110 - A Multi-Center Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis Lung Disease (P08642)

A Phase 3 interventional study of Denufosol tetrasodium Inhalation Solution in Cystic Fibrosis, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 5 Years and older. Per ClinicalTrials.gov, last updated 2015-11-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
308
Allocation
Not applicable
Ages
5 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Cystic Fibrosis by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Cystic Fibrosis · Merck & Co., Inc.

Enrollment
3rd of 10
308 · median 68
Started
2009
the only one that year
Phase 3
3 of 10
none open now
Registered
8th of 10
by date

Among the 10 studies in Cystic Fibrosis by Merck & Co., Inc, this one is the 3rd largest by enrollment, is the only one that started in 2009, is one of 3 in phase 3, and was the 8th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 10 studies in Cystic Fibrosis by Merck & Co., Inc is open now. The open studies under Cystic Fibrosis, anywhere →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 5 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies in Cystic Fibrosis by Merck & Co., Inc as a file.
02

Study summary

The purpose of this study is to obtain data on the potential of long-term treatment with denufosol to improve the clinical course of CF lung disease in patients with mildly impaired lung function and to provide CF patients who completed study 08-110 continued access to denufosol.

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completed Study 08-110

Exclusion criteria

Exclusion Criteria:

  • A female patient will not be eligible for the study if she is of and is pregnant, lactating, and/or not practicing an acceptable method of (e.g., abstinence, hormonal or barrier methods, partner sterilization, or intrauterine device).
  • Have a condition that might affect compliance with study procedures
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
308 participants (actual)

Study arms

  • Experimental
    Denufosol tetrasodium Inhalation Solution

    Drug: Denufosol tetrasodium Inhalation Solution

Interventions

  • DrugDenufosol tetrasodium Inhalation Solution

    60 mg by oral inhalation three times daily

06

What researchers measure

Primary outcomes

  1. Rate of change in lung function, as measured by change in FEV1

    Time frame: 160 Weeks

Secondary outcomes

  1. Change in absolute FEV1 from baseline

    Time frame: Weeks 12, 24, 36, 48, 72, 96, 120, 144, and 160

  2. Change in FEV1 percent predicted value from baseline

    Time frame: Weeks 12, 24, 36, 48, 72, 96, 120, 144, and 160

  3. Change in FEF25%-75% and forced vital capacity (FVC) from baseline

    Time frame: Weeks 12, 24, 36, 48, 72, 96, 120, 144, and 160

  4. Incidence of pulmonary exacerbations

    Time frame: 160 Weeks

  5. Changes in Pseudomonas aeruginosa status

    Time frame: 160 Weeks

  6. Number of days of intravenous (IV) antibiotic use for a respiratory complaint

    Time frame: 160 Weeks

  7. Incidence of hospitalizations/Emergency room (ER) visits for a respiratory complaint

    Time frame: 160 Weeks

  8. Number of days hospitalized for a respiratory complaint

    Time frame: 160 Weeks

  9. Incidence of treatment emergent adverse events (AEs), serious adverse events (SAEs) and withdrawals due to AEs

    Time frame: 160 Weeks

  10. Incidence of patients with significant decrease in absolute FEV1 at any visit from baseline

    Time frame: 160 Weeks

  11. Changes in physical exam findings including height, weight, and body mass index from baseline

    Time frame: Weeks 48, 96, and 160

  12. Changes in hematology, serum chemistry, and urinalysis parameters from baseline

    Time frame: Weeks 24, 48, 72, 96, 120, 144, and 160

  13. Incidence of hospitalizations/ER visits

    Time frame: 160 Weeks

  14. Incidence of early discontinuations from the study

    Time frame: 160 Weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2009, a primary completion of Feb 2011 and a completion of Feb 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 18, 2009
First posted
Feb 19, 2009
Start
Feb 2009
Primary completionActual
Feb 2011
CompletionActual
Feb 2011
Results delay requested
May 20, 2011
Last update
Nov 6, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00846781
Responsible party
Sponsor
First posted
Feb 19, 2009
Start date
Feb 2009
Primary completion
Feb 2011
Completion
Feb 2011
Last update
Nov 6, 2015

Study contacts

Lynn Smiley, MD
study director · Medical Monitor

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion